Paul M Barr

Summary

Affiliation: Case Western Reserve University
Country: USA

Publications

  1. ncbi The role of bortezomib in the treatment of lymphoma
    Paul Barr
    Department of Hematology, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio 44106, USA
    Cancer Invest 25:766-75. 2007
  2. ncbi Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma
    Paul M Barr
    Department of Medicine, University Hospitals Case Medical Center, Cleveland, OH 44106, USA
    Br J Haematol 147:89-96. 2009
  3. ncbi Non-Hodgkin's lymphoma in the elderly
    Paolo F Caimi
    Department of Medicine, Case Comprehensive Cancer Center, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio 44106, USA
    Drugs Aging 27:211-38. 2010
  4. ncbi Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts
    Hillard M Lazarus
    Department of Medicine, Division of Hematology Oncology, Case Comprehensive Cancer Center, University Hospitals Case Medical Center, Cleveland, Ohio 44106, USA
    Biol Blood Marrow Transplant 17:970-8. 2011
  5. ncbi Targeting Bcl-2 based on the interaction of its BH4 domain with the inositol 1,4,5-trisphosphate receptor
    Yi Ping Rong
    Department of Medicine, Comprehensive Cancer Center and University Hospital of Cleveland, Case Western Reserve University, Cleveland, OH 44106, USA
    Biochim Biophys Acta 1793:971-8. 2009
  6. ncbi Correlation between ZAP-70, phospho-ZAP-70, and phospho-Syk expression in leukemic cells from patients with CLL
    David Kaplan
    Department of Pathology, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio 44106, USA
    Cytometry B Clin Cytom 78:115-22. 2010
  7. ncbi Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant
    Paul M Barr
    Department of Medicine, Case Comprehensive Cancer Center, University Hospitals Case Medical Center, Cleveland, Ohio 44106, USA
    Am J Hematol 84:484-7. 2009
  8. ncbi Follicular non-Hodgkin lymphoma: long-term results of stem-cell transplantation
    Paul M Barr
    Department of Medicine, Case Comprehensive Cancer Center, University Hospitals Case Medical Center, Cleveland, OH 44106, USA
    Curr Opin Oncol 20:502-8. 2008

Detail Information

Publications8

  1. ncbi The role of bortezomib in the treatment of lymphoma
    Paul Barr
    Department of Hematology, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio 44106, USA
    Cancer Invest 25:766-75. 2007
    ..In this review, we will detail the clinical results and ongoing trials utilizing bortezomib in Hodgkin's and non-Hodgkin's lymphoma...
  2. ncbi Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma
    Paul M Barr
    Department of Medicine, University Hospitals Case Medical Center, Cleveland, OH 44106, USA
    Br J Haematol 147:89-96. 2009
    ..Cumulative myelosuppression and neuropathy was observed. The combination of fludarabine, bortezomib, and rituximab appears to be an active regimen with manageable toxicity for relapsed NHL...
  3. ncbi Non-Hodgkin's lymphoma in the elderly
    Paolo F Caimi
    Department of Medicine, Case Comprehensive Cancer Center, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio 44106, USA
    Drugs Aging 27:211-38. 2010
    ..Highly selected individuals up to age 70 years may attain long-term survival benefit from autoHCT, although transplant-related mortality is higher than in younger patients...
  4. ncbi Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts
    Hillard M Lazarus
    Department of Medicine, Division of Hematology Oncology, Case Comprehensive Cancer Center, University Hospitals Case Medical Center, Cleveland, Ohio 44106, USA
    Biol Blood Marrow Transplant 17:970-8. 2011
    ..Prompt recognition of this condition and protracted treatment with nonabsorbable or systemic corticosteroids or the combination may lead to resolution...
  5. ncbi Targeting Bcl-2 based on the interaction of its BH4 domain with the inositol 1,4,5-trisphosphate receptor
    Yi Ping Rong
    Department of Medicine, Comprehensive Cancer Center and University Hospital of Cleveland, Case Western Reserve University, Cleveland, OH 44106, USA
    Biochim Biophys Acta 1793:971-8. 2009
    ..In addition, we speculate on how the BH4 domain of Bcl-2 can be targeted therapeutically not only for diseases associated with apoptosis resistance, but also for diseases associated with accelerated cell death...
  6. ncbi Correlation between ZAP-70, phospho-ZAP-70, and phospho-Syk expression in leukemic cells from patients with CLL
    David Kaplan
    Department of Pathology, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio 44106, USA
    Cytometry B Clin Cytom 78:115-22. 2010
    ....
  7. ncbi Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant
    Paul M Barr
    Department of Medicine, Case Comprehensive Cancer Center, University Hospitals Case Medical Center, Cleveland, Ohio 44106, USA
    Am J Hematol 84:484-7. 2009
    ..Future investigations of agents targeting the protein kinase C pathway may benefit from early response assessment using flow cytometry to evaluate T-cell apoptosis...
  8. ncbi Follicular non-Hodgkin lymphoma: long-term results of stem-cell transplantation
    Paul M Barr
    Department of Medicine, Case Comprehensive Cancer Center, University Hospitals Case Medical Center, Cleveland, OH 44106, USA
    Curr Opin Oncol 20:502-8. 2008
    ..Hematopoietic stem-cell transplantation is an effective treatment option for follicular lymphoma. This review summarizes recent updates of the literature focusing on the available long-term follow-up of high-dose therapeutic approaches...